Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.

Lutz Naehrlich; Annalisa Orenti; Fiona Dunlevy; Irena Kasmi; Satenik Harutyunyan; Andreas Pfleger; Svetlana Keegan; Géraldine Daneau; Guergana Petrova; Duška Tješić-Drinković; +33 more... Panayiotis Yiallouros; Alena Bilkova; Hanne Vebert Olesen; Pierre-Régis Burgel; Tsitsino Parulava; Filia Diamantea; Andrea Párniczky; Edward F McKone; Meir Mei-Zahav; Marco Salvatore; Carla Colombo; Elina Aleksejeva; Kestutis Malakauskas; Marc Schlesser; Stojka Fustik; Oxana Turcu; Domenique Zomer-van Ommen; Anita Senstad Wathne; Łukasz Woźniacki; Luísa Pereira; Liviu Pop; Nataliya Kashirskaya; Milan Rodić; Hana Kayserova; Uro Krivecs; Pedro Mondejar-Lopez; Isabelle de Monestrol; Deniz Dogru; Halyna Makukh; Rebecca Cosgriff; Silke van Koningsbruggen-Rietschel; Andreas Jung; European Cystic Fibrosis COVID project group; (2021) Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. JOURNAL OF CYSTIC FIBROSIS, 20 (4). pp. 566-577. ISSN 1569-1993 DOI: 10.1016/j.jcf.2021.03.017
Copy

BACKGROUND: Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF). METHODS: We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection. RESULTS: Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant. Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133). CONCLUSIONS: SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.


picture_as_pdf
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.pdf
subject
Published Version
Available under Creative Commons: 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads